Robert Baltera Jr., serving as a director at Palisade Bio, Inc. (NASDAQ: PALI), has executed a series of acquisitions totaling $102,084 in the company's common stock. These purchases were completed across two distinct trading days in early July 2026, specifically on July 6 and July 7. The weighted average prices for these transactions fell within a narrow band, ranging from $2.0348 to $2.052 per share, indicating a focused accumulation strategy by the insider.
On July 6, 2026, Baltera Jr. initiated the buying activity by acquiring 20,000 shares of Palisade Bio common stock. The weighted average price for this initial block was $2.052 per share. The execution of this purchase involved multiple transactions, with individual share prices fluctuating between $2.04 and $2.068. This initial acquisition was followed the next day, July 7, 2026, when Baltera Jr. purchased an additional 30,000 shares. The weighted average price for this subsequent transaction was slightly lower at $2.0348 per share, with individual share prices ranging from $2.00 to $2.07. Following the completion of these acquisitions, Baltera Jr.'s direct holdings in Palisade Bio have increased to a total of 416,904 shares of common stock.
The timing of this insider purchase is notable given the recent performance and fundamental developments surrounding Palisade Bio. The stock has experienced significant volatility, surging 184% over the past year, yet it remains down 13% year-to-date as of the transaction date. Market analysis suggests that the stock currently appears overvalued relative to its Fair Value estimate, placing it among companies identified on the Most Overvalued list. Investors are advised to consider the stock's high volatility, a characteristic highlighted in recent InvestingPro Tips which also note the availability of 12 additional exclusive tips for subscribers.
Concurrently, Palisade Bio is advancing its clinical pipeline, having received FDA clearance for its Investigational New Drug application for PALI-2108. This regulatory milestone permits the company to initiate a Phase 2 clinical trial for patients suffering from moderately to severely active ulcerative colitis. The global trial, designated as ASCENTRA-UC, is designed to enroll up to 204 patients across North America and Europe. Enrollment for the trial is expected to begin in the second half of 2026, with primary efficacy results anticipated to be reported in the second half of 2027.
Following the FDA clearance, H.C. Wainwright reiterated a Buy rating for Palisade Bio and set a price target of $7.00. The company has also expanded its leadership team by appointing Robert Baltera and Jordan Zwick to its Board of Directors, bringing significant biotech expertise to the organization. Baltera, who serves as a Senior Advisor at Frazier Life Sciences, brings a history of leadership in the biopharmaceutical industry, including a previous role as CEO at Amira Pharmaceuticals. Additionally, Palisade Bio has presented additional pharmacokinetic data for PALI-2108, indicating promising results regarding metabolite concentration and exposure ratios. These developments underscore the company's ongoing efforts to advance its ulcerative colitis treatment pipeline within the broader biotech sector.